[go: up one dir, main page]

WO2013048174A3 - Kit pour le diagnostic de l'adénocarcinome pancréatique, comprenant des moyens de mesure du ca19-9, de la cathepsine d et la métalloprotéinase matricielle-7 - Google Patents

Kit pour le diagnostic de l'adénocarcinome pancréatique, comprenant des moyens de mesure du ca19-9, de la cathepsine d et la métalloprotéinase matricielle-7 Download PDF

Info

Publication number
WO2013048174A3
WO2013048174A3 PCT/KR2012/007895 KR2012007895W WO2013048174A3 WO 2013048174 A3 WO2013048174 A3 WO 2013048174A3 KR 2012007895 W KR2012007895 W KR 2012007895W WO 2013048174 A3 WO2013048174 A3 WO 2013048174A3
Authority
WO
WIPO (PCT)
Prior art keywords
pancreatic adenocarcinoma
kit
diagnosing pancreatic
cathepsin
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/007895
Other languages
English (en)
Korean (ko)
Other versions
WO2013048174A2 (fr
Inventor
이수연
김종원
박형두
이종균
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samsung Life Public Welfare Foundation
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Publication of WO2013048174A2 publication Critical patent/WO2013048174A2/fr
Publication of WO2013048174A3 publication Critical patent/WO2013048174A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un réactif permettant de diagnostiquer l'adénocarcinome du pancréas, comprenant un moyen de mesure de la concentration sanguine du CA19-9, de la cathepsine D et de la métalloprotéinase matricielle 7. L'invention porte également sur un kit pour le diagnostic de l'adénocarcinome pancréatique contenant ledit réactif pour le diagnostic de l'adénocarcinome pancréatique, et sur un procédé permettant de fournir les informations nécessaires au diagnostic de l'adénocarcinome pancréatique au moyen dudit kit. Ce kit permet de réaliser un diagnostic précoce de l'adénocarcinome pancréatique et peut ainsi être largement utilisé pour traiter plus efficacement l'adénocarcinome pancréatique.
PCT/KR2012/007895 2011-09-28 2012-09-28 Kit pour le diagnostic de l'adénocarcinome pancréatique, comprenant des moyens de mesure du ca19-9, de la cathepsine d et la métalloprotéinase matricielle-7 Ceased WO2013048174A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110098548A KR101358510B1 (ko) 2011-09-28 2011-09-28 카텝신 ｄ와 매트릭스 메탈로프로틴나제-7의 측정수단을 포함하는 췌장암 진단용 키트
KR10-2011-0098548 2011-09-28

Publications (2)

Publication Number Publication Date
WO2013048174A2 WO2013048174A2 (fr) 2013-04-04
WO2013048174A3 true WO2013048174A3 (fr) 2013-05-23

Family

ID=47996643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007895 Ceased WO2013048174A2 (fr) 2011-09-28 2012-09-28 Kit pour le diagnostic de l'adénocarcinome pancréatique, comprenant des moyens de mesure du ca19-9, de la cathepsine d et la métalloprotéinase matricielle-7

Country Status (2)

Country Link
KR (1) KR101358510B1 (fr)
WO (1) WO2013048174A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205374A1 (fr) * 2013-06-20 2014-12-24 The Trustees Of The University Of Pennsylvania Méthodes permettant de diagnostiquer un cancer du pancréas
KR101665165B1 (ko) * 2013-12-04 2016-10-12 단국대학교 산학협력단 신규한 rna 앱타머 및 그의 용도
KR20150129932A (ko) 2014-05-12 2015-11-23 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트
CN114250298B (zh) * 2020-09-23 2024-09-24 中国医学科学院北京协和医院 胰腺导管腺癌的dna甲基化标志物及其应用
WO2025064551A1 (fr) * 2023-09-19 2025-03-27 The Board Of Trustees Of The Leland Stanford Junior University Cathepsines à glycoprotéine active ciblées et procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126243A (en) * 1982-08-09 1992-06-30 Centocor, Inc. Immunoassay for carbohydrate antigenic determinant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126243A (en) * 1982-08-09 1992-06-30 Centocor, Inc. Immunoassay for carbohydrate antigenic determinant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JI KON RYU ET AL.: "Molecular Diagnosis and Tumor Markers in Pancreatic Cancer", KOREAN JOURNAL OF HBP SURGERY, vol. 8, no. 2, June 2004 (2004-06-01), pages 69 - 75, XP003031635 *
LUCIE E. JONES ET AL.: "Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase 7 predicts poor survival", CLINICAL CANCER RESEARCH, vol. 10, no. 8, 2004, pages 2832 - 2845, XP003031633 *
MAIKEN THYREGOD JOERGENSEN ET AL.: "Comparison of Circulating MMP-9, TIMP-1 and CA19-9 in the Detection of Pancreatic Cancer", ANTICANCER RESEARCH, vol. 30, no. 2, 2010, pages 587 - 592, XP003031632 *
RU CHEN ET AL.: "Quantitative Proteomics Analysis Reveals That Proteins Differentially Expressed in Chronic Pancreatitis Are Also Frequently Involved in Pancreatic Cancer", MOLECULAR & CELLULAR PROTEOMICS, vol. 6, no. 8, 2007, pages 1331 - 1342, XP003031634 *

Also Published As

Publication number Publication date
WO2013048174A2 (fr) 2013-04-04
KR101358510B1 (ko) 2014-02-06
KR20130034505A (ko) 2013-04-05

Similar Documents

Publication Publication Date Title
WO2013066369A3 (fr) Procédés de détection de maladie du greffon contre l'hôte
WO2010091049A3 (fr) Diagnostic et traitement du cancer
WO2013190075A3 (fr) Biomarqueurs spécifiques pour un carcinome hépatocellulaire (hcc)
WO2012021407A3 (fr) Biomarqueurs pour accident vasculaire cérébral
WO2011015944A3 (fr) Utilisation d'adn libre en tant que prédicteur précoce de la gravité d'une pancréatite aiguë
WO2009085234A3 (fr) Utilisation d'un micro-arn à titre de marqueur biologique d'une activité médicamenteuse immunomodulatoire
HK1211370A1 (en) User interface for analyte monitoring systems
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
WO2013048174A3 (fr) Kit pour le diagnostic de l'adénocarcinome pancréatique, comprenant des moyens de mesure du ca19-9, de la cathepsine d et la métalloprotéinase matricielle-7
WO2010085542A3 (fr) Biomarqueurs associés à la dégénérescence maculaire liée à l'âge (dmla)
WO2010120942A3 (fr) Modèles de modification des histones utilisables à des fins de diagnostic clinique et de pronostic en matière de cancer
MX2013005139A (es) Kit guiado de prueba estructurada.
WO2011015602A3 (fr) Biomarqueurs du cancer du poumon
GB201201766D0 (en) Method
HK1209673A1 (en) Using modulators of ccr5 for treating cancer
WO2011052906A3 (fr) Utilisation de eif3m pour le diagnostic et le traitement du cancer
WO2013009146A3 (fr) Marqueur pour le diagnostic d'une rétinopathie diabétique
MX381530B (es) Método in vitro para el diagnóstico de la enfermedad de niemann-pick.
WO2013062261A3 (fr) Marqueur récemment identifié du cancer du côlon et trousse de diagnostic l'utilisant
WO2011133036A3 (fr) Moyens et méthodes de détermination du risque de maladie cardiovasculaire
WO2012004276A3 (fr) Marqueurs biologiques multiprotéines de la sclérose latérale amyotrophique dans les cellules mononucléaires du sang périphérique, procédés et kits de diagnostic
EP2684881A4 (fr) Composé ayant un chromophore fluorescent, capteur de concentration d'ion comprenant le composé, réactif comprenant le composé, coffret de réactif comportant le réactif, précurseur du composé, et procédé de synthèse du composé
WO2012081007A3 (fr) Procédés de diagnostic et de traitement du cancer du pancréas
CA2837488C (fr) Procede et dispositif pour determiner la teneur en toxines uremiques liees aux proteines et moyennes dans un fluide biologique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12836486

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12836486

Country of ref document: EP

Kind code of ref document: A2